Coronavirus: China approves first local neutralising antibody cocktail for high-risk patients

China’s medical products regulator approved the use of the country’s first locally developed neutralising antibody cocktail therapy for Covid-19 on Wednesday.Brii Biosciences said its therapy showed an 80 per cent reduction of hospital admissions and death in a global phase 3 trial with 847 non-hospitalised coronavirus patients, adding that no serious adverse events were identified.The National Medical Products Administration granted approval for the combination of two antibodies to be used for…

Read the original article at South China Morning Post